OptimizeRxOPRX
OPRX
About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Employees: 136
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 18
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 85 [Q3] → 85 (+0) [Q4]
7.19% less ownership
Funds ownership: 67.58% [Q3] → 60.39% (-7.19%) [Q4]
43% less capital invested
Capital invested by funds: $95.6M [Q3] → $54.1M (-$41.5M) [Q4]
87% less call options, than puts
Call options by funds: $75K | Put options by funds: $569K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.50
5%
downside
Avg. target
$8.70
51%
upside
High target
$13
125%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
JMP Securities Constantine Davides 40% 1-year accuracy 12 / 30 met price target | 38%upside $8 | Market Outperform Reiterated | 6 Feb 2025 |
RBC Capital Sean Dodge 48% 1-year accuracy 19 / 40 met price target | 4%upside $6 | Sector Perform Downgraded | 8 Jan 2025 |
Lake Street Eric Martinuzzi 50% 1-year accuracy 13 / 26 met price target | 90%upside $11 | Buy Reiterated | 24 Dec 2024 |
B. Riley Securities Neil Chatterji 100% 1-year accuracy 2 / 2 met price target | 125%upside $13 | Buy Maintained | 24 Dec 2024 |
Stephens & Co. Jeff Garro 50% 1-year accuracy 3 / 6 met price target | 5%downside $5.50 | Equal-Weight Initiated | 20 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 months ago
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.
Neutral
GlobeNewsWire
3 months ago
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
Neutral
Seeking Alpha
3 months ago
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Steve Silvestro - President Conference Call Participants Ryan Daniels - William Blair & Company, LLC Sean Dodge - RBC Capital Markets Kyle Bauser - B. Riley Securities David Grossman - Stifel Financial Constantine Davides - Citizens JMP Stephanie Davis - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call.
Positive
Zacks Investment Research
3 months ago
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago.
Positive
Zacks Investment Research
3 months ago
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains?
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
3 months ago
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call.
Positive
Zacks Investment Research
4 months ago
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
5 months ago
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initial program, however, ultimately resulted in a multi-solution, multi-brand engagement while DAAP conversion continues through the client's internal review and approval process. This engagement represents an ongoing expansion of investment by a top-tier pharma client in OptimizeRx's solutions and demonstrates the value of scaling them across several brands in its portfolio, driving stronger commercial performance from brands through HCP and DTC marketing alignment.
Neutral
GlobeNewsWire
5 months ago
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
The availability of Micro-Neighborhood ® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing
Positive
Zacks Investment Research
5 months ago
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for OptimizeRx (OPRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™